Lupin gains on getting tentative approval from USFDA for Tenofovir Alafenamide tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Lupin is currently trading at Rs. 774.75, up by 4.15 points or 0.54% from its previous closing of Rs. 770.60 on the BSE.
The scrip opened at Rs. 772.45 and has touched a high and low of Rs. 783.20 and Rs. 772.45 respectively. So far 28544 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 678.65 on 07-Mar-2022.
Last one week high and low of the scrip stood at Rs. 783.20 and Rs. 764.85 respectively. The current market cap of the company is Rs. 35208.18 crore.
The promoters holding in the company stood at 46.78%, while Institutions and Non-Institutions held 41.85% and 11.37% respectively.
Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Tenofovir Alafenamide Tablets, 25 mg, to market a generic equivalent of Vemlidy Tablets, 25 mg, of Gilead Sciences, Inc. (Gilead). This product will be manufactured at Lupin's Nagpur facility in India.
Tenofovir Alafenamide Tablets (RLD: Vemlidy Tablets) had estimated annual sales of USD 484.2 million in the U.S. (IQVIA MAT December 2021)
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.
.jpg)
